Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

References

• ZamboniWCConcept and clinical evaluation of carrier-mediated anticancer agentsOncologist200813324826018378535
   PubMed Web of Science ®Google Scholar
• InnocentiFKroetzDLSchuetzEComprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokineticsJ Clin Oncol200927162604261419349540
   PubMed Web of Science ®Google Scholar
• SlatterJGSchaafLJSamsJPPharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsDrug Metab Dispos200028442343310725311
   PubMed Web of Science ®Google Scholar
• ZamboniWCLiposomal, nanoparticle, and conjugated formulations of anticancer agentsClin Cancer Res200511238230823416322279
   PubMed Web of Science ®Google Scholar
• ZamboniWCStewartCFThompsonJRelationship between topotecan systemic exposure and tumor response in human neuroblastoma xenograftsJ Natl Cancer Inst19989075055119539245
   PubMedGoogle Scholar
• StewartCFZamboniWCCromWRTopoisomerase I interactive drugs in children with cancerInvest New Drugs199614137478880392
   PubMed Web of Science ®Google Scholar
• XieRMathijssenRHSparreboomAVerweijJKarlssonMOClinical pharmacokinetics of irinotecan and its metabolites in relation with diarrheaClin Pharmacol Ther200272326527512235447
   PubMed Web of Science ®Google Scholar
• AllenTMHansenCPharmacokinetics of stealth versus conventional liposomes: effect of doseBiochim Biophys Acta1991106821331411911826
   PubMed Web of Science ®Google Scholar
• PapahadjopoulosDAllenTMGabizonASterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyProc Natl Acad Sci U S A1991882411460114641763060
   PubMed Web of Science ®Google Scholar
• SongGWuHYoshinoKZamboniWCFactors affecting the pharmacokinetics and pharmacodynamics of liposomal drugsJ Liposome Res201222317719222332871
   PubMed Web of Science ®Google Scholar
• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncologyCancer Res20137382412241723423979
   PubMed Web of Science ®Google Scholar
• Ahmad KhanbeigiRKumarASadoukiFThe delivered dose: applying particokinetics to in vitro investigations of nanoparticle internalization by macrophagesJ Control Release2012162225926622824784
   PubMed Web of Science ®Google Scholar
• ShahNBVercellottiGMWhiteJGFeganAWagnerCRBischofJCBlood-nanoparticle interactions and in vivo biodistribution: impact of surface PEG and ligand propertiesMol Pharm2012982146215522668197
   PubMedGoogle Scholar
• SkoczenSLPotterTMDobrovolskaiaMAIn vitro analysis of nanoparticle uptake by macrophages using chemiluminescenceMethods Mol Biol201169725526121116975
   PubMedGoogle Scholar
• MoghimiSMParhamifarLAhmadvandDParticulate systems for targeting of macrophages: basic and therapeutic conceptsJ Innate Immun201245–650952822722900
   PubMed Web of Science ®Google Scholar
• AndersenAJWibroePPMoghimiSMPerspectives on carbon nanotube-mediated adverse immune effectsAdv Drug Deliv Rev201264151700170522634159
   PubMed Web of Science ®Google Scholar
• CristRMGrossmanJHPatriAKCommon pitfalls in nanotechnology: lessons learned from NCI’s Nanotechnology Characterization LaboratoryIntegr Biol (Camb)201251667322772974
   PubMed Web of Science ®Google Scholar
• CaronWPSongGKumarPRawalSZamboniWCInterpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agentsClin Pharmacol Ther201291580281222472987
   PubMed Web of Science ®Google Scholar
• SidoneBJEdwardsRPZamboniBAStrychorSMarucaLJZamboniWCEvaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil)Paper presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical ApplicationsOctober 22–26, 2007San Francisco, CA, USA
   Google Scholar
• ZamboniWCStrychorSMarucaLPharmacokinetic study of PEGylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesClin Pharmacol Ther200986551952619675541
   PubMed Web of Science ®Google Scholar
• WuHRamanathanRKZamboniBAMechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patientsInt J Nanomedicine201275555556423112576
   PubMed Web of Science ®Google Scholar
• ZamboniWCMarucaLJStrychorSBidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumorsJ Liposome Res201121215816520626314
   PubMed Web of Science ®Google Scholar
• De MartinisMModestiMGinaldiLPhenotypic and functional changes of circulating monocytes and polymorphonuclear leucocytes from elderly personsImmunol Cell Biol200482441542015283852
   PubMed Web of Science ®Google Scholar
• ZamboniWCStrychorSJosephEPlasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenograftsClin Cancer Res200713237217722318056203
   PubMed Web of Science ®Google Scholar
• InfanteJRKeedyVLJonesSFPhase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsCancer Chemother Pharmacol201270569970522941375
   PubMed Web of Science ®Google Scholar
• ZamboniWCTondaMENew designs of clinical trialsHighlights in Oncology Practice200018127
   Google Scholar
• InfanteJRKeedyVLJonesSFPhase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumorsCancer Chemother Pharmacol201270569970522941375
   PubMed Web of Science ®Google Scholar
• KuritaAKanedaNHigh-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKTJ Chromatogr B Biomed Sci Appl1999724233534410219676
   PubMedGoogle Scholar
• GabrielssonJLWeinerDLPharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications3rd edLondon, UKTaylor and Francis2000
   Google Scholar
• RosnerGFundamentals of Biostatistics5th edPacific Grove, CA, USADuxbury2000
   Google Scholar
• MaedaHWuJSawaTMatsumuraYHoriKTumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ Control Release2000651–227128410699287
   PubMed Web of Science ®Google Scholar
• MarkmanMGordonANMcGuireWPMuggiaFMLiposomal anthracycline treatment for ovarian cancerSemin Oncol2004316 Suppl 139110515717739
   PubMed Web of Science ®Google Scholar
• KrownSENorthfeltDWOsobaDStewartJSUse of liposomal anthracyclines in Kaposi’s sarcomaSemin Oncol2004316 Suppl 13365215717737
   PubMed Web of Science ®Google Scholar
• RoyVLaPlantBRGrossGGBaneCLPalmieriFMPhase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)Ann Oncol200920344945319087987
   PubMed Web of Science ®Google Scholar
• DeLoiaJAZamboniWCJonesJMStrychorSKelleyJLGallionHHExpression and activity of taxane-metabolizing enzymes in ovarian tumorsGynecol Oncol2008108235536018063021
   PubMed Web of Science ®Google Scholar
• WeisbergSPMcCannDDesaiMRosenbaumMLeibelRLFerranteAWJrObesity is associated with macrophage accumulation in adipose tissueJ Clin Invest2003112121796180814679176
   PubMed Web of Science ®Google Scholar
• WellenKEHotamisligilGSObesity-induced inflammatory changes in adipose tissueJ Clin Invest2003112121785178814679172
   PubMed Web of Science ®Google Scholar
• SparreboomAZamboniWCCancer Chemotherapy and Biotherapy: Principles and Practice4th edPhiladelphia, PA, USALippincott Williams & Wilkins2005
   Google Scholar
• StewartCFZamboniWCCromWRTopoisomerase I interactive drugs in children with cancerInvest New Drugs19961437478880392
   PubMed Web of Science ®Google Scholar
• ZamboniWCEdwardsRPMountzJMThe development of liposomal and nanoparticle anticancer agents: methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for pharmacokinetic (PK) and pharmacodynamic (PD) dispositionPaper presented at the NSTI Nanotechnology ConferenceMay 7–11, 2007Boston, MA, USA
   Google Scholar